The Burrill Report


The Burrill Report (June 18, 2012): Genentech's Big Bet on New Cancer Drugs (.MP3,20.72 Mb)

News of impressive late-stage clinical results for Genentech’s breast cancer antibody-drug conjugate T-DM1 was one of the major stories to emerge from this year’s American Society of Clinical Oncology meeting. It is the most advanced antibody-drug conjugate in Genentech’s growing pipeline of this class of drugs. We spoke to Stuart Lutzker, head of the clinical oncology early development group for Genentech, about the technical challenges antibody-drug conjugates pose, their potential, and how the company is leveraging its expertise in monoclonal antibodies to make a big bet on the role these drugs will play in the future of cancer care.











June 15, 2012
http://www.burrillreport.com/article-genentechs_big_bet_on_new_cancer_drugs.html